Recurrent arterial and venous thrombosis in a 16-year-old boy in the course of primary antiphospholipid syndrome despite treatment with low-molecular-weight heparin: a case report

Journal of Medical Case Reports

Elzbieta Smolewska¹  Jerzy Stanczyk¹  Joanna Szymanska-Kaluza¹  Joanna Lipinska¹ 

[1] Department of Pediatric Cardiology and Rheumatology, Medical University of Lodz, 36/50 Sporna St., 91-738, Lodz, Poland

关键词: Venous thrombosis;    Systemic lupus erythematosus;    Arterial thrombosis;    Antiphospholipid syndrome;   

Others  :  825504
DOI  :  10.1186/1752-1947-7-221

 received in 2013-05-29, accepted in 2013-07-25,  发布年份 2013

【 摘 要 】

Introduction

Antiphospholipid syndrome is a multisystem autoimmune disease characterized by arterial and/or venous thrombosis and persistent presence of antiphospholipid antibodies. It can be a primary disease or secondary when associated with other autoimmune diseases.

Case presentation

We present a case of a 16-year-old Caucasian boy with a massive arterial and venous thrombosis in his lower limbs as well as in his central nervous system with clinical symptoms such as headaches and chorea. He did not present any clinical or laboratory signs of a systemic inflammatory connective tissue disease, including systemic lupus erythematosus. Based on the clinical picture and results of the diagnostic tests (positive antibodies against β₂-glycoprotein and a high titre of anticardiolipin antibodies) we finally diagnosed primary antiphospholipid syndrome. During a 9-month follow up after the acute phase of the disease, he was treated with low-molecular-weight heparin. Neurological symptoms were relieved. Features of recanalization in the vessels of his lower limbs were observed. After a subsequent 6 months, because of the failure of preventive treatment – an incident of thrombosis of the vessels of his testis – treatment was modified and heparin was replaced with warfarin.

Conclusion

Although the preventive treatment with warfarin in our patient has continued for 1 year of follow up without new symptoms, further observation is needed.

【 授权许可】

   
2013 Biernacka-Zielinska et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Myones BL: Update on antiphospholipid syndrome in children. Curr Rheumatol Rep 2011, 13:86-89.
• [2]Hunt BJ: Pediatric antiphospholipid antibodies and antiphospholipid syndrome. Semin Thromb Hemost 2008, 34:274-281.
• [3]Avcin T: Antiphospholipid syndrome in children. Curr Opin Rheumatol 2008, 20:595-600.
• [4]Rigante D, Gaspari S, Bersani G, Stabile A: Antiphospholipid syndrome: clinical spectrum and therapeutical/prophylactic strategies in the pediatric population. Eur Rev Med Pharmacol Sci 2008, 12:47-53.
• [5]Cimaz R, Descloux E: Pediatric antiphospholipid syndrome. Rheum Dis Clin North Am 2006, 32:553-573.
• [6]Levine JS, Branch DW, Rauch J: The antiphospholipid syndrome. N Engl J Med 2002, 347:145-146.
• [7]Biggioggero M, Meroni PL: The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 2010, 9(5):A299-A304.
• [8]Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, de Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Vlachoyiannopoulos PG, Krilis SA: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
• [9]Cervera R, Tektonidou MG, Espinosa G, Cabral AR, González EB, Erkan D, Vadya S, Adrogué HE, Solomon M, Zandman-Goddard G, Shoenfeld Y: Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations. Lupus 2011, 20(2):174-181.
• [10]Avcin T, Silverman ED: Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome. Lupus 2007, 16(8):627-633.
• [11]Avcin T, Cimaz R, Silverman ED, Cervera R, Gattorno M, Garay S, Berkun Y, Sztajnbok FR, Silva CA, Campos LM, Saad-Magalhaes C, Rigante D, Ravelli A, Martini A, Rozman B, Meroni PL: Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics 2008, 122(5):e1100-e1107.
• [12]Gibson NS, Sohne M, Gerdes VE, Nijkeuter M, Buller HR: The importance of clinical probability assessment in interpreting a normal d-dimer in patients with suspected pulmonary embolism. Chest 2008, 134(4):789-793.
• [13]Parker RI: Thrombosis in the pediatric population. Crit Care Med 2010, 38(2 Suppl):S71-S75.
• [14]Ravelli A, Martini A: Antiphospholipid syndrome in pediatrics. Rheum Dis Clin North Am 2007, 33:499-523.
• [15]Berkun Y, Kenet G: Pediatric antiphospholipid syndrome. Isr Med Assoc J 2008, 10:45-47.
• [16]Hunt BJ: Paediatric antiphospholipid antibodies and antiphospholipid syndrome. Semin Thromb Hemost 2008, 343:274-281.
• [17]Meroni P, Borghi M, Raschi E, Tedesco F: Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011, 7:330-339.